Open an account

Amplify Weight Loss Drug & Treatment ETF

THNR · ETF

$24.70−$0.25 (−1.00%)TodayMarket closed ·
No price history for this range.

About THNR

THNR was created on 2024-05-21 by Amplify. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 5.61m in AUM and 22 holdings. THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

Issuer
Amplify
Tracks
VettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net
Expense ratio
0.59%
Assets under management
$5.73M
Inception
May 21, 2024
Asset class
Equity
Website
amplifyetfs.com

THNR key statistics

Price-earnings ratio
0.00
Average volume
762
Volume
385
Open price
$24.98
High today
$24.70
Low today
$24.70
52 Week high
$27.94
52 Week low
$22.89

Amplify Weight Loss Drug & Treatment ETF (THNR) at a glance

As of Oct 23, 2026, Amplify Weight Loss Drug & Treatment ETF (THNR) shares are priced at $24.70, giving the company a price-to-earnings ratio of 0.00.

Volume so far is 385 shares, below the average of 762 shares a day.

Over the past year Amplify Weight Loss Drug & Treatment ETF has ranged from $22.89 to $27.94, and now sits 36% of the way up that range.

THNR news

  • Vandana Singh

    Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval

  • Chandrima Sanyal

    Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.